SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-002377
Filing Date
2022-02-03
Accepted
2022-02-03 16:15:11
Documents
14
Period of Report
2022-01-28
Items
Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 FORM 8-K navb20220203_8k.htm   iXBRL 8-K 31119
2 EXHIBIT 99.1 ex_331813.htm EX-99.1 12365
  Complete submission text file 0001437749-22-002377.txt   180984

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA navb-20220128.xsd EX-101.SCH 3592
4 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE navb-20220128_def.xml EX-101.DEF 11423
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE navb-20220128_lab.xml EX-101.LAB 15309
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE navb-20220128_pre.xml EX-101.PRE 11583
8 EXTRACTED XBRL INSTANCE DOCUMENT navb20220203_8k_htm.xml XML 2572
Mailing Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017
Business Address 4995 BRADENTON AVENUE SUITE 240 DUBLIN OH 43017 6147937500
NAVIDEA BIOPHARMACEUTICALS, INC. (Filer) CIK: 0000810509 (see all company filings)

IRS No.: 311080091 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35076 | Film No.: 22588459
SIC: 2835 In Vitro & In Vivo Diagnostic Substances